Chrome Plugin Live! Redefine the way you read FinTwit š Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
NBSE
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
globenewswire.com
7 hours ago
investorplace.com
8 hours ago
investorplace.com
9 hours ago
pennystocks.com
12 hours ago
zacks.com
12 hours ago
globenewswire.com
16 hours ago
Forecast
2024-Revenue
100%2024-EPS
2024-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
N/A(N/A)
Number of analyst
N/A
Last analyst upgrade/downgrade
Oppenheimer
downgradePrevious: Not converted
2022-10-21
Now: Perform
Relative Strength
NBSE
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
-0.01Ā ( -1.56%)
Relative Strenght
2
Volume Buzz
-30%
Earning Acce
Yes
Dist 52w H.
91%Earnings Growth
YoY
Current
Estimates
Q4.21
N/A
-4.80
vsĀ -3.60
Q1.22
N/A
-6.00
vsĀ -4.80
Q2.22
N/A
-5.20
vsĀ -5.80
Q3.22
N/A
-4.80
vsĀ -4.20
Q4.22
N/A
-2.60
vsĀ -4.80
Q1.23
N/A
-2.40
vsĀ -6.00
Q2.23
N/A
-1.26
vsĀ -5.20
Q3.23
N/A
-0.95
vsĀ -4.80
Q4.23
N/A
-2.00
vsĀ -2.60
Q1.24
+165%
1.57
vsĀ -2.40
Sales Growth
YoY
Current
Estimates
Q2.21
NA
NAĀ vsĀ NA
Q3.21
NA
NAĀ vsĀ NA
Q4.21
NA
NAĀ vsĀ NA
Q1.22
NA
NAĀ vsĀ NA
Q2.22
NA
NAĀ vsĀ NA
Q3.22
NA
NAĀ vsĀ NA
Q4.22
NA
NAĀ vsĀ NA
Q1.23
NA
NAĀ vsĀ NA
Q2.23
NA
NAĀ vsĀ NA
Q3.23
NA
NAĀ vsĀ NA
Return on Equity
QoQ
Q2.21
-14%
-0.14
vsĀ -0.23
Q3.21
-13%
-0.13
vsĀ -0.14
Q4.21
-16%
-0.16
vsĀ -0.13
Q1.22
-26%
-0.26
vsĀ -0.16
Q2.22
-28%
-0.28
vsĀ -0.26
Q3.22
-33%
-0.33
vsĀ -0.28
Q4.22
-24%
-0.24
vsĀ -0.33
Q1.23
-28%
-0.28
vsĀ -0.24
Q2.23
-31%
-0.31
vsĀ -0.28
Q3.23
-20%
-0.20
vsĀ -0.31
Institutionnal Ownership
QoQ
Q1.22
44
44
vsĀ 45
-2%
Q2.22
36
36
vsĀ 44
-18%
Q3.22
36
36
vsĀ 36
NA
Q4.22
32
32
vsĀ 36
-11%
Q1.23
35
35
vsĀ 32
9%
Q2.23
26
26
vsĀ 35
-26%
Q3.23
20
20
vsĀ 26
-23%
Q4.23
21
21
vsĀ 20
5%
Q1.24
17
17
vsĀ 21
-19%
Q2.24
1
1
vsĀ 17
-94%
Quote Panel
Key Metrics